Clinical Trial of 12 weeks of oral DAA therapy for HCV Genotype 1-infected Japanese Patients

Clinical Trial of 12 weeks of oral DAA therapy for HCV Genotype 1-infected Japanese Patients - 12ODTG1

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000019212

Enrollment

Registered

2015-10-02

Start date

2015-10-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis C (genotype 1)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: HCV genotype 1 patients Chronic hepatitis or compensated liver cirrhosis Patients with viremia

Exclusion criteria

Exclusion criteria: Patients who have allergy to DAAs

Design outcomes

Primary

Measure	Time frame
Sustained virological response	—

Countries

Japan

Contacts

Public ContactKen Sato

Gunma University Department of Medicine and Molecular Science

satoken@gunma-u.ac.jp027-220-8127

Outcome results